BDO Unibank Inc. is taking a leading role in financing the world’s largest integrated solar and battery storage project, MTerra Solar, which is being built to help meet the Philippines’ rising ...

These BDO codes give rewards such as Memory Fragments, Cron Stones, Enhancement Kits, and more. All of these items are handy for your next session, so we've also detailed ways you can redeem them ...

Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology ...

Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical ...

See the latest BDO Unibank Inc stock price (BDO:XPHS), related news, valuation, dividends and more to help you make your investing decisions.

Panelists discuss how the shift from intravenous (IV) to subcutaneous (SubQ) drug administration is transforming oncology care delivery, highlighting its lasting impact on patient experience ...

Review the current BDO Unibank Inc (BDO:XPHS) dividend yield and history to decide if BDO is the best investment for you.

Study finds abdominal fat causes more blood vessel harm than subcutaneous fat by German Centre for Cardiovascular Research (DZHK) edited by Sadie Harley, reviewed by Andrew Zinin Editors' notes ...

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American Diabetes ...

View the latest BDO Unibank Inc. (BDO) stock price, news, historical charts, analyst ratings and financial information from WSJ.

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings. The new ...

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year.